“The global membrane chromatography market is projected to grow at a CAGR of 18.1%.”
The global membrane chromatography market is expected to reach USD 290.6 million by 2022 from USD 126.6 million in 2017, at a CAGR of 18.1%. Growth in this market can primarily be attributed to factors such as increasing demand for biopharmaceuticals, increasing R&D expenditure in the biopharmaceutical industry, significant benefits of membrane chromatography over conventional chromatography methods, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes. However, the limited use of membrane chromatography in large-scale manufacturing is expected to restrain the growth of this market during the forecast period.

“The ion exchange membrane chromatography segment is expected to account for the largest share in 2017.”
Based on techniques, the membrane chromatography market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography. The ion exchange membrane chromatography segment is expected to account for the largest share of the global membrane chromatography market in 2017. The large share of this segment can be attributed to its wide applications in antibody polishing and virus purification due to the advantages associated with ion exchange membrane chromatography, such as scalability, robustness, disposable nature, high throughput, rapid processing, reduced buffer consumption, and a validation-free environment.
Based on product, the consumables segment is expected to dominate the market in 2017
In 2017, the membrane chromatography consumables segment is expected to account for the largest share of the global market. Growth in this segment can primarily be attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing and lab-scale production and process development processes.
“North America is expected to account for the largest share during the forecast period.”
By region, North America is expected to account for the largest share of the global membrane chromatography market. This large share can be attributed to the increasing demand for biopharmaceuticals and rising R&D expenditure by biopharmaceutical companies in North America. Europe is expected to account for the second-largest share of the membrane chromatography market.
Break-up profile of primaries:
• By Company Type- Tier 40%, Tier 30%, and Tier 30%
• By Designation-C-level-27%, D-level-18%, and Others-55%
• By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global membrane chromatography market are Sartorius (Germany), GE Healthcare (US), Danaher (US), Merck Millipore (US), and 3M (US).
Research Coverage:
The membrane chromatography market in this report is segmented by product, technique, operation mode, and region. The study tracks and analyzes competitive developments such as product launches, collaborations, agreements, partnerships, and acquisitions, and profiles key players and core competencies in the membrane chromatography market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global membrane chromatography market. The report analyzes the market by product, technique, operation mode, and region

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global membrane chromatography market

Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for membrane chromatography products across regions

Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global membrane chromatography market

Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global membrane chromatography market

“The global in vivo toxicology market is projected to grow at a CAGR of 6.9%.”
The in vivo toxicology market is expected to reach USD 6.14 billion by 2022 from an estimated USD 4.40 billion in 2017, at a CAGR of 6.9%. The key factors driving the growth of this market include, increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests. On the other hand, alternative methods to animal testing and disadvantages associated with animal toxicology testing likely to restrain the growth of this market.

“The instruments segment is expected to grow at the highest CAGR during the forecast period”
On the basis of product, the in vivo toxicology market is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models. The instruments segment is expected to grow at the highest rate during the forecast period. The growth of this segment can be attributed to the increasing research on biological samples (such as blood and urine) using bioanalytical equipment.

“Chronic toxicity testing holds the largest share in the global in vivo toxicology market by testing type”
Based on testing type, the global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic toxicity testing. In 2017, chronic toxicity testing segment is estimated to hold the largest share in the global in vivo toxicology market. The large share of this market is attributed to the high cost of in vivo testing for more than 90 days, maintaining the animals, quality of tests, and the long duration of the tests performed.

“The immunotoxicity segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2017, the immunotoxicity segment is expected to account for the largest share in the in vivo toxicology market, this segment is also expected to grow at the highest CAGR during the forecast period. Rising demand for the development of biologics for autoimmune diseases and cancer and the increasing growth of biosimilars in oncology are driving the growth of this segment.

“China to witness the highest growth in the APAC region during the forecast period (2017-2022)”
In the APAC region, China is expected to witness the highest growth during the study period. The rising R&D funding and collaborations; initiatives taken by the Chinese government to promote life science research; and the strong trend of commercialization of biotechnology research are contributing to the growth of in vivo toxicology market in China.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–29%, Tier 2–35% and Tier 3–36%
• By Designation – C-level–39%, Director Level–35%, Others–26%
• By Region – North America–42%, Europe–36%, Asia Pacific–13%, RoW–9%

The major players in the global in vivo toxicology market are Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), and The Jackson Laboratory (US).
Research Coverage:
The report analyzes the in vivo toxicology market and aims at estimating the market size and future growth potential of this market based on various aspects such as products, testing type, toxicity endpoint, testing facility and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in-turn would help them, garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by key players in the global in vivo toxicology market. The report analyzes the global in vivo toxicology market by product, testing type, toxicity endpoint, testing facility, and region
• Product and Service Innovation: Detailed insights on upcoming trends and product and service launches in the global in vivo toxicology market
• Market Development: Comprehensive information about the lucrative emerging markets by product, testing type, toxicity endpoint, testing facility, and region
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global in vivo toxicology market
• Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

“The global microplate systems market projected to grow at a CAGR of 4.0%.”
The global microplate systems market is expected to reach USD 996.9 million by 2022 from USD 820.3 million in 2017 at a CAGR of 4.0%. This market is experiencing significant growth due to increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases.

“Microplate Readers are expected to grow at the highest CAGR during the forecast period.”
Based on product and service, the market is segmented into microplate readers, microplate pipetting systems and dispensers, microplate washers, and other products. The microplate readers segment is expected to hold the largest share of the market in 2017 and projected to register the highest CAGR during the forecast period. High demand for these systems due to increasing number of research activities are the key factors driving the growth of this segment.

“Biotechnology and pharmaceutical companies is expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and research and academic institutes. The biotechnology and pharmaceutical companies segment is estimated to hold the largest share the microplate systems market in 2017. It is projected to register the highest growth during the forecast period due to increasing government support in the form of funding for biotech and pharma research.

“Asia Pacific to witness the highest growth during the forecast period.”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing focus on research-related funding activities by government organizations, increasing healthcare investments, increasing ageing population, and increasing prevalence of diseases.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 30%; Tier 2 – 42%; Tier 3 – 28%
• By Designation: C-level- 25%; D-level- 45%; Others- 30%
• By Region: North America-48%; Europe-29%; Asia Pacific-20%; Latin America- 19%, Rest of the World-4%

List of companies profiled in the report
• BioTek (US)
• Danaher (US)
• PerkinElmer (US)
• Tecan (Switzerland)
• Thermo Fisher (US)
• BMG LABTECH (Germany)
• BERTHOLD (Germany)
• Agilent (US)
• Bio-Rad (US)
• Promega (US)
• Biochrom (UK)
• Corning (US)
• Lonza (Switzerland)
• Rayto (China)
• Mindray (China)
Research Coverage:
The report provides an overview of the microplate systems market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall microplate systems market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

The guidewires market projected to grow at a CAGR of 4.8%
The global guidewires market is projected to reach USD 764.0 million by 2022 from USD 605.2 million in 2017, at a CAGR of 4.8%. The growth witnessed by guidewires is mainly driven by growing target disease incidence, continuous product commercialization by major manufacturers and favorable medical reimbursements for guidewires in developed countries. The government initiatives to control the burden of healthcare-associated infections (HAIs) in developed countries and the increasing healthcare expenditure across emerging markets are also driving the growth of the market. However, high cost of surgical guidewires, spending cuts & excise duties on medical devices and dearth of skilled surgeons for minimally invasive surgeries are the key challenges faced by a majority of the guidewires manufacturers across the globe.
“The hybrid guidewires segment is poised to be the fastest-growing during the forecast period.”
On the basis of material, the global guidewires market is segmented into nitinol guidewires, stainless steel guidewires, and hybrid guidewires. The hybrid guidewires segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to rising adoption among medical professionals owing to their technological and procedural advantages, growing awareness among surgeons about the clinical benefits of these guidewires, and the evolving reimbursement scenario for target procedures across key healthcare markets.
“The cardiology applications segment is poised to be the fastest-growing during the forecast period.”
On the basis of application, the global guidewires market is segmented into cardiology, vascular, neurology, urology, gastroenterology, oncology, and otolaryngology. The cardiology applications segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising adoption of guidewires among cardiologists owing to procedural and technical benefits offered by nitinol materials used for manufacturing cardiology guidewires.

“Asia Pacific is expected to register the highest growth rate during the forecast period.”
Geographically, the guidewires market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The highest CAGR for the APAC guidewires market can be attributed to the rising adoption of guidewires due to their decreasing costs (owing to the increase in localized manufacturing and strengthening of distribution networks of key product manufacturers) and increasing healthcare expenditure across key APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type – Tier 1 – 25%, Tier 2 – 30% and Tier 3 – 45%
• By Designation – C level – 26%, Director level – 30%, Others – 44%
• By Region – North America – 34%, Europe – 26%, APAC – 23%, RoW – 17%

The global guidewires market is competitive, with a large number of global and local players. In 2016, the market was dominated by Boston Scientific (US), Medtronic (Ireland), Abbott (US), Cook Group (US), and Terumo (Japan). Product launches, market expansions, strategic acquisitions, partnerships, agreements & collaborations were the major strategies adopted by market players to achieve growth in the market.

Research Coverage
This report studies the guidewires market based on material, product, application, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for the market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
From an insights perspective, this research report has focused on various levels of analysis—industry trends, market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the guidewires market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the belowmentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the major players in the guidewires market. The report analyzes the guidewires market based on material, product, application, end user, and region
• Product Development: Detailed insights on the research and development activities and product launches in the guidewires market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various guidewires across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the guidewires market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the guidewires market

“The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%.”
The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Growth in this market is mainly driven the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligonucleotides from the growing field of molecular diagnostics, rising venture capital investments, and increasing demand for synthetic genes. However, the price erosion of synthesized oligos and lack of regulations for therapeutic oligos are some factors that may hinder the growth of this market.

“Synthesized oligonucleotides are expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into synthesized oligonucleotides, reagents, and equipment. The synthesized oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics is a key market driver in this segment. The rising availability and demand for custom oligos also contribute to the growth of the synthesized oligonucleotides market.

“The research segment is expected to hold the largest share of the market in 2017.”
Based on application, the market is segmented into research, diagnostics, and therapeutics. The research segment is estimated to hold the largest share of the oligonucleotide synthesis market in 2017. The market growth for research applications is mainly driven by the developments in the fields of gene synthesis and NGS. Oligos are widely used in technologies such as PCR, qPCR, gene synthesis, isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS).

“Academic research institutes are expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end users. The academic research institutes segment is expected to dominate the market during the forecast period. With the increasing funding pouring into institutes to conduct research, the demand for oligonucleotides is bound to increase. To meet this need, companies are launching products and entering into agreements with different research institutes to supply oligonucleotides for research purposes. For instance, in August 2015, Eurofins Genomics launched NGS tests for the identification of non-targeted microorganisms, including 16S Microbiome Profiling for academia and research.

“APAC to witness the highest growth during the forecast period.”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 – 46%; Tier 3 – 18%.
• By Designation: C-level- 26%; D-level- 45%; Others- 29%.
• By Region: North America-41%; Europe-31%; Asia Pacific-20%; Latin America- 5%, Middle East and Africa-3%

List of companies profiled in the report
• Agilent Technologies (US)
• ATDBio (UK)
• Bio-Synthesis (US)
• BioAutomation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign (Japan)
• GE Healthcare (US)
• GenScript (US)
• Integrated DNA Technologies (IDT) (US)
• Nitto Denko Avecia (US)
• Thermo Fisher Scientific (US)
• TriLink Biotechnologies (US)
• Sigma-Aldrich Corporation (Sigma-Aldrich) (US) (part of Merck KGAA (Germany)
Research Coverage:
The report provides an overview of the oligonucleotide synthesis market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall oligonucleotide synthesis market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

“The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 7.6% between 2018 and 2023.”
The CRO services market is expected to reach USD 56.34 billion by 2023 from USD 39.13 billion in 2018, at a CAGR of 7.6%. Increased outsourcing of R&D activities and increasing number of clinical trials are some of the major factors driving the growth of this market. However, intense competition in the CRO services market is one of the major challenges for the players operating in the CRO services market.
“Laboratory services segment to witness the highest growth rate during the forecast period.”
Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing number of pipeline drugs and growing outsourcing of laboratory services by pharmaceutical and biopharmaceutical companies.
“Oncology segment to grow at the highest CAGR from 2018 to 2023.”
Oncology segment is expected to register the highest CAGR during the forecast period. The increasing number of clinical trials and rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.
“APAC to witness the highest growth rate during the forecast period.”
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.
Break of primary participants:
• By Company Type – Tier 1: 21%, Tier 2–26%, and Tier 3–53%
• By Designation – C Level: 32%, Director Level: 26%, and Others: 42%
• By Region – North America: 26%, Europe: 35%, Asia Pacific: 20%, Latin America: 11%, and the Middle East & Africa: 8%
Research Coverage:
The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.
The report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
 Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
 Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
 Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
 Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment
is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region’s large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–33% and Tier 3–21%
• By Designation – C Level–43%, Director Level–35%, Others–22%
• By Region – North America–34%, Europe–26%, Asia Pacific–24%, Latin America–12%, Middle East and Africa- 4%
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
• Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.